Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

One treatment-related death occurred in the combination therapy group.

Adding the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab to percutaneous hepatic perfusion may improve survival outcomes in patients with ...

IDEAYA Biosciences (NASDAQ:IDYA) executives outlined multiple upcoming clinical catalysts at Citi’s 2026 Virtual Oncology ...

Completed Phase I DIONE-01 study demonstrates clinical activity and long-term safety of roginolisib, a unique allosteric modulator of PI3Kδ Patients with uveal melanoma showed a doubling of overall ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 December 2024) The European Organisation for Research and Treatment of Cancer (EORTC), an independent clinical cancer research ...

A form of T-cell therapy targeting a highly expressed antigen in uveal melanoma, a rare form of the disease, appears to be tolerable and efficacious, even though the tumors are considered to be ...

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication ...

ROCHESTER, Minnesota — Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better ...

A study led by Dr. J. William Harbour of UT Southwestern Medical Center marks a shift in how doctors predict the spread of uveal melanoma. A recent study led by Dr. J. William Harbour of UT ...